Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome

Int Immunopharmacol. 2021 Apr;93:107239. doi: 10.1016/j.intimp.2020.107239. Epub 2020 Dec 2.

Abstract

Since SARS-CoV-2 infection is rapidly spreading all around the world, affecting many people and exhausting health care resources, therapeutic options must be quickly investigated in order to develop a safe and effective treatment. The present study was designed to evaluate the safety and efficacy of convalescent plasma (CP) for treating severe cases of COVID-19 who developed acute respiratory distress syndrome (ARDS). Among 64 confirmed cases of severe COVID-19 with ARDS in this study, 32 patients received CP besides first line treatment. Their clinical response and outcome in regard to disease severity and mortality rate were evaluated and compared with the other 32 patients in the control group who were historically matched while randomly chosen from previous patients with the same conditions except for receiving CP therapy. Analysis of the data was performed using SPSS software. Patients with plasma therapy showed improvements in their clinical outcomes including a reduction in disease severity in terms of SOFA and APACHE II scores, the length of ICU stay, need for noninvasive ventilation and intubation and also showed an increase in oxygenation. They also showed reduction in mortality which was statistically significant in less severe cases with mild or moderate ARDS. Early administration of the convalescent plasma could successfully contribute to the treatment of severe COVID-19 patients with mild or moderate ARDS at risk of progressing to critical state.

Keywords: ARDS; COVID-19; Convalescent plasma; Passive immunization.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / therapeutic use
  • COVID-19 / immunology
  • COVID-19 / therapy*
  • COVID-19 / virology
  • Female
  • Humans
  • Immunization, Passive / adverse effects
  • Immunization, Passive / methods
  • Male
  • Middle Aged
  • Respiratory Distress Syndrome / immunology
  • Respiratory Distress Syndrome / therapy*
  • Respiratory Distress Syndrome / virology
  • SARS-CoV-2 / isolation & purification
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult

Substances

  • Antiviral Agents

Supplementary concepts

  • COVID-19 serotherapy